Home / TRAIL/TNFSF10 / Recombinant Human TRAIL/TNFSF10 Protein

Recombinant Human TRAIL/TNFSF10 Protein

Catalog #: 375-TL
54 Citations 1 Review Datasheet / COA / SDS

Carrier Free

Catalog # Availability Size / Price Qty
375-TL-010/CF

With Carrier

Catalog # Availability Size / Price Qty
375-TL-010
Best Seller
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (54)
FAQs
Reviews (1)
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human TRAIL/TNFSF10 Protein Summary

Product Specifications

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cytotoxicity assay using L‑929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. Matthews, N. and M.L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 221. The ED50 for this effect is 4-12 ng/mL.
The apoptotic effect of soluble trimeric rhTRAIL can be enhanced by oligimerization of the soluble rhTRAIL through the use of a cross-linking antibody Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050). The ED50 for this effect is 1-4 ng/mL.
Note: This is one of multiple forms available for this protein. Check R&D Systems' website, www.RnDSystems.com, for a complete listing of the variants.
Source
Mouse myeloma cell line, NS0-derived human TRAIL/TNFSF10 protein
Thr95-Gly281, with an N-terminal Met and 6-His tag
Accession #
P50591
N-terminal Sequence
Analysis
Met
Structure / Form
Noncovalently-linked homotrimer and disulfide-linked homodimer
Predicted Molecular Mass
21 kDa (monomer)
SDS-PAGE
24 kDa, reducing conditions

Product Datasheets

You must select a language.

x

375-TL (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

375-TL/CF (carrier free)

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

375-TL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 20 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -70 °C under sterile conditions after reconstitution.

375-TL/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: TRAIL/TNFSF10

TRAIL (TNF-related apoptosis-inducing ligand), also known as APO-2 ligand, is a type II transmembrane protein with a carboxy-terminal extracellular domain which exhibits homology to other TNF family members. In the new TNF superfamily nomenclature, TRAIL is referred to as TNFSF10. Human TRAIL cDNA encodes a 281 amino acid (aa) residue protein with an amino-terminal intracellular domain of 17 residues and a predicted internal hydrophobic domain between residues 18 and 38. The extracellular carboxy-terminal domain contains a potential N-linked glycosylation site at amino acid residue 109. Among TNF family members, TRAIL is most homologous to FAS ligand, sharing 28% amino acid sequence identity in their extracellular domains. Mouse TRAIL has also been cloned. The human TRAIL shares 65% amino acid sequence identity with mouse TRAIL and is active on mouse cells. Both membrane bound and soluble TRAIL have been shown to induce rapid apoptosis of many transformed cell lines. Like most TNF family members, the bioactive TRAIL exists as a homotrimer. TRAIL transcripts have been shown to be constitutively expressed in a variety of human tissues. A family of TRAIL receptors, including two receptors that tranduce the apoptotic signals and two TRAIL decoy receptors that function to antagonize TRAIL-induced apoptosis, have been identified (1 - 3). Osteoprotegerin has been identified as a fifth TRAIL receptor (4).

References
  1. Golstein, P. (1997) Current Biology 7:R750.
  2. Wiley, S.R. et al. (1995) Immunity 3:673.
  3. Pitti, R.M. et al. (1996) J. Biol. Chem. 271:12687.
  4. Emery, J. et al. (1998) J. Biol. Chem. 273:14363.
Long Name
TNF-related Apoptosis-inducing Ligand
Entrez Gene IDs
8743 (Human); 22035 (Mouse); 246775 (Rat)
Alternate Names
Apo-2 ligand; APO2L; Apo-2Ltumor necrosis factor (ligand) family, member 10; APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta; CD253 antigen; CD253; Protein TRAIL; TL2; TNF-related apoptosis-inducing ligand; TNFSF10; TRAIL; TRAILTNF-related apoptosis inducing ligand TRAIL; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor ligand superfamily member 10

Citations for Recombinant Human TRAIL/TNFSF10 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

54 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. The tetrapeptide sequence of IL-18 and IL-1? regulates their recruitment and activation by inflammatory caspases
    Authors: Exconde, PM;Hernandez-Chavez, C;Bourne, CM;Richards, RM;Bray, MB;Lopez, JL;Srivastava, T;Egan, MS;Zhang, J;Yoo, W;Shin, S;Discher, BM;Taabazuing, CY;
    Cell reports
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines
    Authors: Bravo Perina, L;Faria Gomes, IN;Alcantara Pelloso, AR;Silva, VAO;Rebolho Batista Arantes, LM;Eliseo Melendez, M;
    Scientific reports
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. BdLT-Seq as a barcode decay-based method to unravel lineage-linked transcriptome plasticity
    Authors: Y Shlyakhtin, B Bloechl, MM Portal
    Nature Communications, 2023-02-25;14(1):1085.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defense.
    Authors: Bhuyan S, Pal B, Pathak L, Saikia P, Mitra S, Gayan S, Mokhtari R, Li H, Ramana C, Baishya D, Das B
    Front Immunol, 2022-09-29;13(0):933329.
    Species: Complex Species Category
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5
    Authors: SM Woo, S Kim, SU Seo, S Kim, JW Park, G Kim, YR Choi, K Hur, TK Kwon
    Cell Death & Disease, 2022-09-24;13(9):821.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
    Authors: J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang
    Nature Communications, 2022-03-25;13(1):1606.
    Species: Human
    Sample Types: Transduced Whole Cells
    Applications: Bioassay
  7. Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
    Authors: BT Wang, T Kothambawa, L Wang, TJ Matthew, SE Calhoun, AK Saini, MF Kotturi, G Hernandez, EW Humke, MS Peterson, AM Sinclair, BA Keyt
    Molecular Cancer Therapeutics, 2021-10-28;0(0):.
    Species: Human
    Sample Types: Whole Cell
    Applications: Bioassay
  8. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating�hepatic dipeptidyl peptidase-4 expression
    Authors: M Lee, E Shin, J Bae, Y Cho, JY Lee, YH Lee, BW Lee, ES Kang, BS Cha
    Sci Rep, 2020-11-10;10(1):19429.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  9. The Obesity-Susceptibility Gene TMEM18 Promotes Adipogenesis through Activation of PPARG
    Authors: K Landgraf, N Klöting, M Gericke, N Maixner, E Guiu-Jurad, M Scholz, AV Witte, F Beyer, JT Schwartze, M Lacher, A Villringer, P Kovacs, A Rudich, M Blüher, W Kiess, A Körner
    Cell Rep, 2020-10-20;33(3):108295.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  10. TRAIL inhibits oxidative stress in human aortic endothelial cells exposed to pro-inflammatory stimuli
    Authors: H Forde, E Harper, KD Rochfort, RG Wallace, C Davenport, D Smith, PM Cummins
    Physiol Rep, 2020-10-01;8(20):e14612.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  11. Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation
    Authors: SM Woo, SU Seo, P Kubatka, KJ Min, TK Kwon
    Biomolecules, 2019-12-06;9(12):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  12. Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation
    Authors: M Hong, J Li, S Li, M M Almutair
    Cells, 2019-11-19;8(11):.
    Species: Human, Xenograft
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay, In Vivo
  13. The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1
    Authors: SP O'Hara, PL Splinter, CE Trussoni, E Guicciardi, NP Splinter, MS Al Suraih, N Nasser-Gho, D Stollenwer, GJ Gores, NF LaRusso
    J. Biol. Chem., 2019-10-28;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis
    Authors: WY Kong, ZY Yee, CW Mai, CM Fang, S Abdullah, SC Ngai
    Heliyon, 2019-09-19;5(9):e02468.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  15. MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer Cells
    Authors: EA Kim, JH Jang, EG Sung, IH Song, JY Kim, TJ Lee
    Int J Mol Sci, 2019-07-19;20(14):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  16. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma
    Authors: SM Woo, KJ Min, SU Seo, S Kim, P Kubatka, JW Park, TK Kwon
    Int J Mol Sci, 2019-07-02;20(13):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
    Authors: EB Jo, YS Lee, H Lee, JB Park, H Park, YL Choi, D Hong, SJ Kim
    BMC Cancer, 2019-05-24;19(1):496.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Activated NK cells kill hepatic stellate cells via p38/PI3K signaling in a TRAIL-involved degranulation manner
    Authors: T Li, Y Yang, H Song, H Li, A Cui, Y Liu, L Su, IN Crispe, Z Tu
    J. Leukoc. Biol., 2019-02-12;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer
    Authors: BR Kim, SH Park, YA Jeong, YJ Na, JL Kim, MJ Jo, S Jeong, HK Yun, SC Oh, DH Lee
    Oncogene, 2019-01-28;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Aldehyde Dehydrogenase 1 (ALDH1) Promotes the Toxicity of TRAIL in Non-Small Cell Lung Cancer Cells via Post-Transcriptional Regulation of MEK-1 Expression
    Authors: S Tian, DH Liu, D Wang, F Ren, P Xia
    Cell. Physiol. Biochem., 2018-11-16;51(1):217-227.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  21. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis
    Authors: B Lian, D Yang, Y Liu, G Shi, J Li, X Yan, K Jin, X Liu, J Zhao, W Shang, R Zhang
    Cell. Physiol. Biochem., 2018-09-26;49(6):2151-2162.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease
    Authors: CJ Williams, U Qazi, M Bernstein, A Charniak, C Gohr, E Mitton-Fit, A Ortiz, L Cardinal, AT Kaell, AK Rosenthal
    Osteoarthr. Cartil., 2018-03-22;0(0):.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  23. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease
    Authors: AW Clarke, L Poulton, D Shim, D Mabon, D Butt, M Pollard, V Pande, J Husten, J Lyons, C Tian, AG Doyle
    MAbs, 2018-03-05;0(0):1-43.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance (SPR
  24. ShDcR3 sensitizes TRAIL-resistant HCC cells by inducing caspase-dependent apoptosis while suppressing NF-?B dependent cFLIPL expression
    Authors: DY Liang, W Huang, Q Chang, YQ Hou
    PLoS ONE, 2018-02-14;13(2):e0191545.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  25. Silencing of peroxiredoxin II by promoter methylation is necessary for the survival and migration of gastric cancer cells
    Authors: SH Hong, C Min, Y Jun, DJ Lee, SH Kim, JH Park, JH Cheong, YJ Park, SY Kim, S Lee, SW Kang
    Exp. Mol. Med., 2018-02-09;50(2):e443.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  26. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF Mutated human Colorectal Cancer
    Authors: P Zhang, H Kawakami, W Liu, X Zeng, K Strebhardt, K Tao, S Huang, FA Sinicrope
    Mol. Cancer Res., 2017-12-12;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  27. Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin
    Authors: SM Woo, KJ Min, SU Seo, S Kim, JW Park, DK Song, HS Lee, SH Kim, TK Kwon
    Oncotarget, 2017-11-20;8(63):106672-106684.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  28. Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis
    Authors: MJ Mitchell, J Webster, A Chung, PP Guimarães, OF Khan, R Langer
    Nat Commun, 2017-03-20;8(0):14179.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  29. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-? through up-regulation of TNF receptor 1 in lung cancer cells.
    Authors: Bo Ra You, Bo Ram Han, Woo Hyun Park
    Oncotarget, 2017-03-14;0(0):1949-2553.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  30. Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy
    Authors: J Yang, Y Wu, X Wang, L Xu, X Zhao, Y Yang
    Tumour Biol, 2017-03-01;39(3):1010428317692.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  31. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis
    Authors: C Liang, Y Xu, G Li, T Zhao, F Xia, G Li, D Zhang, J Wu
    Onco Targets Ther, 2017-01-18;10(0):417-428.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  32. Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL
    Authors: SH Lee, SK Hyun, HB Kim, CD Kang, SH Kim
    Oncol. Res., 2016-10-27;24(6):495-509.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis
    Oncotarget, 2016-04-19;7(16):21416-27.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  34. Tissue Inhibitor of Metalloproteinase-4 Triggers Apoptosis in Cervical Cancer Cells.
    Authors: Lizarraga F, Ceballos-Cancino G, Espinosa M, Vazquez-Santillan K, Maldonado V, Melendez-Zajgla J
    PLoS ONE, 2015-08-20;10(8):e0135929.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  35. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.
    Authors: Meng X, Koh B, Zhang J, Flatten K, Schneider P, Billadeau D, Hess A, Smith B, Karp J, Kaufmann S
    J Biol Chem, 2014-07-25;289(30):20543-58.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  36. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications.
    Authors: Jang, Jae Youn, Kim, Seong-Ju, Cho, Eun Kyun, Jeong, Soung Wo, Park, Eui Ju, Lee, Woong Ch, Lee, Sae Hwan, Kim, Sang Gyu, Kim, Young Se, Kim, Hong Soo, Kim, Boo Sung, Lin, Wenyu, Chung, Raymond
    PLoS ONE, 2014-06-13;9(6):e98171.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  37. Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency.
    Authors: Mathieu J, Zhou W, Xing Y, Sperber H, Ferreccio A, Agoston Z, Kuppusamy K, Moon R, Ruohola-Baker H
    Cell Stem Cell, 2014-03-20;14(5):592-605.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  38. Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels.
    Authors: You B, Park W
    Int J Oncol, 2014-03-12;44(5):1745-55.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  39. XIAP antagonist embelin inhibited proliferation of cholangiocarcinoma cells.
    Authors: Wehrkamp, Cody J, Gutwein, Ashley R, Natarajan, Sathish, Phillippi, Mary Ann, Mott, Justin L
    PLoS ONE, 2014-03-06;9(3):e90238.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  40. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Authors: Kim, Seong Mu, Woo, Ji Sun, Jeong, Chang Hy, Ryu, Chung He, Jang, Jae-Deog, Jeun, Sin-Soo
    Stem Cells Transl Med, 2014-01-16;3(2):172-82.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  41. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation.
    Authors: Yang, Hongmei, Chen, Xuanyu, Wang, Xuegang, Li, Yansheng, Chen, Shaoyong, Qian, Xiaohui, Wang, Rong, Chen, Li, Han, Weiwei, Ruan, Anming, Du, Quanshen, Olumi, Aria F, Zhang, Xiaoping
    Mol Cancer Res, 2013-12-02;12(2):217-27.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  42. Sialic acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and exerts synergistic antitumor effects with TRAIL.
    Authors: Tatsuta T, Hosono M, Takahashi K, Omoto T, Kariya Y, Sugawara S, Hakomori S, Nitta K
    Int J Oncol, 2013-11-28;44(2):377-84.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  43. Characterization of cytosolic proliferating cell nuclear antigen (PCNA) in neutrophils: antiapoptotic role of the monomer.
    Authors: De Chiara A, Pederzoli-Ribeil M, Mocek J, Candalh C, Mayeux P, Millet A, Witko-Sarsat V
    J Leukoc Biol, 2013-07-03;94(4):723-31.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  44. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation.
    Authors: Akimoto, Keiko, Kimura, Kenichi, Nagano, Masumi, Takano, Shingo, To'a Salazar, Georgina, Yamashita, Toshihar, Ohneda, Osamu
    Stem Cells Dev, 2013-02-04;22(9):1370-86.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  45. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012-07-26;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  46. Granule exocytosis mediates immune surveillance of senescent cells.
    Authors: Sagiv, A, Biran, A, Yon, M, Simon, J, Lowe, S W, Krizhanovsky, V
    Oncogene, 2012-07-02;32(15):1971-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  47. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
    Authors: Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, Cao L
    Clin Cancer Res, 2011-03-08;17(10):3181-92.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  48. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival.
    Authors: Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H
    Clin. Cancer Res., 2011-02-24;17(7):1741-52.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  49. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Authors: Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH
    Biochem. Pharmacol., 2009-01-24;77(8):1328-36.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  50. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
    Authors: Chamoux E, Houde N, L'Eriger K, Roux S
    J. Cell. Physiol., 2008-08-01;216(2):536-42.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  51. TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN.
    Authors: Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP
    J. Interferon Cytokine Res., 2008-04-01;28(4):253-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  52. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
    Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
    Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  53. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis.
    Authors: Dumitru CA, Gulbins E
    Oncogene, 2006-04-24;25(41):5612-25.
    Species: Human, Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  54. Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
    Authors: Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I
    Int. J. Cancer, 2006-04-15;118(8):1901-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

  1. This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?

    • The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human TRAIL/TNFSF10 Protein

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human TRAIL/TNFSF10 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human TRAIL/TNFSF10 Protein
By Sijie Bi on 07/21/2016
Application: Cell Viability Assay
Reason for Rating: Results met expectation
Other Recombinant Human TRAIL/TNFSF10 Protein 375-TL